JP2021523931A5 - - Google Patents

Info

Publication number
JP2021523931A5
JP2021523931A5 JP2021500503A JP2021500503A JP2021523931A5 JP 2021523931 A5 JP2021523931 A5 JP 2021523931A5 JP 2021500503 A JP2021500503 A JP 2021500503A JP 2021500503 A JP2021500503 A JP 2021500503A JP 2021523931 A5 JP2021523931 A5 JP 2021523931A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
eudragit
formulation according
mc1r
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021500503A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021523931A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/023575 external-priority patent/WO2019183472A1/en
Publication of JP2021523931A publication Critical patent/JP2021523931A/ja
Publication of JP2021523931A5 publication Critical patent/JP2021523931A5/ja
Pending legal-status Critical Current

Links

JP2021500503A 2018-03-23 2019-03-22 メラノコルチン受容体特異的ペプチド製剤及び消化管特異的送達方法 Pending JP2021523931A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862647000P 2018-03-23 2018-03-23
US62/647,000 2018-03-23
PCT/US2019/023575 WO2019183472A1 (en) 2018-03-23 2019-03-22 Melanocortin receptor-specific peptide formulations and methods for gastrointestinal tract-specific delivery

Publications (2)

Publication Number Publication Date
JP2021523931A JP2021523931A (ja) 2021-09-09
JP2021523931A5 true JP2021523931A5 (enExample) 2022-03-28

Family

ID=67988087

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021500503A Pending JP2021523931A (ja) 2018-03-23 2019-03-22 メラノコルチン受容体特異的ペプチド製剤及び消化管特異的送達方法

Country Status (13)

Country Link
US (1) US20220088146A1 (enExample)
EP (1) EP3768245A4 (enExample)
JP (1) JP2021523931A (enExample)
KR (1) KR102743821B1 (enExample)
CN (1) CN112188888A (enExample)
AU (2) AU2019239300A1 (enExample)
BR (1) BR112020019128A2 (enExample)
CA (1) CA3095036A1 (enExample)
EA (1) EA202092275A1 (enExample)
IL (1) IL277496B2 (enExample)
MX (1) MX2020009900A (enExample)
PH (1) PH12020551596A1 (enExample)
WO (1) WO2019183472A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021158463A1 (en) 2020-02-03 2021-08-12 Palatin Technologies, Inc. Diamine-linked receptor-specific cyclic peptides
TW202440065A (zh) * 2022-12-28 2024-10-16 日商中外製藥股份有限公司 包含分散對象物質的固體分散體、包含其之醫藥組合物及其製造方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7645459B2 (en) * 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of bisphosphonates
FR2937868B1 (fr) * 2008-11-04 2010-11-05 Galderma Res & Dev Composes antagonistes des recepteurs de la melanocortine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
BRPI1009644B1 (pt) * 2009-06-08 2022-02-08 Palatin Technologies, Inc Peptídeo cíclico ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica e uso da composição farmacêutica
WO2010144341A2 (en) * 2009-06-08 2010-12-16 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides
AU2010321738B2 (en) * 2009-11-23 2016-07-14 Palatin Technologies, Inc. Melanocortin-1 receptor-specific cyclic peptides
US8759386B2 (en) * 2011-01-24 2014-06-24 Boehringer Ingelheim International Gmbh Pyrazole compounds as CRTH2 antagonists
KR102038677B1 (ko) * 2011-06-14 2019-10-30 입센 파마 에스.에이.에스 활성 성분으로 멜라노코르틴 수용체 리간드를 함유하는 지속-방출형 조성물
SI2659881T1 (en) * 2012-04-30 2018-03-30 Tillotts Pharma Ag Formulation of the delayed release medicinal product
UA119335C2 (uk) * 2013-12-11 2019-06-10 Айронвуд Фармасьютикалз, Інк. Композиції лінаклотиду з затриманим вивільненням
US20150307754A1 (en) * 2014-04-28 2015-10-29 Celanese Acetate Llc Adhesives that include highly-plasticized cellulose esters and methods and articles relating thereto
US10588864B2 (en) * 2016-03-11 2020-03-17 Gateway Pharmaceuticals LLC Pharmaceutical compositions for colon-specific delivery

Similar Documents

Publication Publication Date Title
ES2582453T3 (es) Forma farmacéutica oral sólida contra el uso indebido y dotada de un perfil específico de liberación modificada
ES2459018T3 (es) Formulaciones de efectores de la unión estrecha
JP3806740B2 (ja) 薬剤運搬組成物
ES2645930T3 (es) Utilización de una mezcla de dos o más materiales entéricos para regular la liberación de fármacos a través de una membrana o matriz para terapias sistémicas
CN1182844C (zh) 富马酸二烷基酯的用途
JP7602324B2 (ja) 重水素化ドンペリドン組成物、方法、及び調製
JP3725542B2 (ja) ピコサルフェート剤形
AU2002226955B2 (en) Pharmaceutical dosage form with multiple coatings
JP2009523175A5 (enExample)
MXPA04003367A (es) Formulacion oral microparticulada galenica para la liberacion retrasada y controlada de principios activos farmaceuticos.
JP3633936B2 (ja) センナ剤形
ES2417330T3 (es) Minicomprimidos farmacéuticos para la liberación sostenida de acetato de flecainida
US20150140089A1 (en) Novel formulations of nitrofurans including nifurtimox with enhanced activity with lower toxicity
JP5778184B2 (ja) 上皮増殖因子の経口投与可能薬学的ペレット
WO2010023690A2 (en) Prolonged release formulation of amisulpride
BR112020003375A2 (pt) composições de amantadina, preparações das mesmas, e métodos de uso
CN105434398B (zh) 一种雷贝拉唑肠溶微丸及其制备方法
JP2021073275A (ja) 甲状腺ホルモン又はそのアナログを提供する組成物及び方法
WO2002004016A1 (fr) Preparations enteriques contenant des peptides physiologiquement actifs
KR20240125702A (ko) 중수소화 돔페리돈 조성물, 방법, 및 제조
US20060165808A1 (en) Microcapsules for the delayed, controlled release of perindopril
US12478612B2 (en) Deuterated domperidone compositions, methods, and preparation
JP2006327943A (ja) 経時的溶出遅延を抑制したテイストマスク錠剤
CA3013123C (en) Deuterated domperidone compositions and methods for therapy of disorders
TWI724084B (zh) 類血管加壓素作用增強劑